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Serglycin has been initially characterized as an intracellular proteoglycan expressed by
hematopoietic cells. All inflammatory cells highly synthesize serglycin and store it in
granules, where it interacts with numerous inflammatory mediators, such as proteases,
chemokines, cytokines, and growth factors. Serglycin is implicated in their storage into the
granules and their protection since they are secreted as complexes and delivered to their
targets after secretion. During the last decade, numerous studies have demonstrated that
serglycin is also synthesized by various non-hematopoietic cell types. It has been shown
that serglycin is highly expressed by tumor cells and promotes their aggressive pheno-
type and confers resistance against drugs and complement system attack. Apart from its
direct beneficial role to tumor cells, serglycin may promote the inflammatory process in the
tumor cell microenvironment thus enhancing tumor development. In the present review,
we discuss the role of serglycin in inflammation and tumor progression.
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INTRODUCTION
Proteoglycans (PGs) are complex macromolecules consisted of
a core protein covalently linked with glycosaminoglycan (GAG)
chains named chondroitin sulfate (CS), dermatan sulfate (DS),
keratan sulfate (KS), heparin (HP), and heparan sulfate (HS).
GAGs are negatively charged polysaccharides comprised of
repeating disaccharides of acetylated hexosamines (N -acetyl-
galactosamine or N -acetyl-glucosamine) and mainly by uronic
acids (d-glucuronic acid or l-iduronic acid) being sulfated at
various positions. KS is composed of disaccharides containing
N -acetyl-glucosamine and galactose (1). PGs are synthesized by
all cells and distributed in all tissues participating in physio-
logical functions and pathologic conditions. According to their
localization they can be divided in three main groups, the cell-
surface associated PGs, such as syndecans and glypicans, the matrix
secreted PGs (e.g., versican, decorin, perlecan) and the intracel-
lular PGs, with serglycin being the only characterized member
of this subfamily to date (1). Numerous studies have demon-
strated significant modifications in PG expression in the tumor
microenvironment and their contribution to carcinogenesis (1,
2). The type and fine structure of GAG chains attached to PGs are
markedly affected in the context of malignant transformation as a
result of the altered expression of GAG-synthesizing enzymes (3).
Structural modifications of GAGs may facilitate tumorigenesis in
various ways, modulating the functions of PGs (3).
Serglycin has been initially considered as a hematopoietic PG
present in intracellular secretory compartments. Recent studies
demonstrated that serglycin is expressed by a variety of cell types
and mediates crucial functions in both normal and pathological
conditions (4, 5). Rat L2 yolk sac tumor serglycin was the first
PG gene to be cloned and remains until today the smallest known
core protein (18 kDa) (6). In human, serglycin consists of a small
core protein (158 amino acids) containing eight serine/glycine
repeats (Figure 1). Each serine of this repeat region is a potential
GAG attachment site. The size of the PG varies according to the
GAG chain length, number, and type (7). Serglycin is expressed
in all normal hematopoietic cells and hematopoietic tumor cell
lines (7–17). In mast cells, eosinophils, neutrophils, and platelets,
serglycin is stored together with other bioactive molecules in gran-
ules and is secreted upon activation. Serglycin is constitutively
secreted by lymphocytes and many hematopoietic tumor cell lines
(7, 8, 16). Serglycin is also expressed in non-hematopoietic cells
including pancreatic acinar cells (18), chondrocytes (19), smooth
muscle cells (20, 21), endothelial cells (20, 22, 23), fibroblasts (20,
24, 25), F9, and NCCIT teratocarcinoma cells (26, 27), murine
embryonic stem cells (28), murine uterine dedicua cells, pari-
etal endoderm, and fetal liver but not yolk sac hematopoietic
cells (29). Recently, it was demonstrated that serglycin is highly
expressed by aggressive nasopharyngeal cancer cells (30). The
type and sulfation of GAG chains attached to the serglycin core
protein, varies between different species and cell types (4, 8, 16,
17, 22, 23, 31–43). For example, serglycin expressed by human
mast calls has been shown to contain both HP and CS chains
enriched in disulfated disaccharides [being sulfated at C4 and
C6 of N -acetyl-galactosamine (CS-E)] attached in separate core
proteins, whereas mouse mast cells synthesize a hybrid HP/CS-E
serglycin. In leukocytes, platelets, myeloma, and endothelial cells,
serglycin contains CS chains that are mainly sulfated at C4 of N -
acetyl-galactosamine (CS-4). Interestingly, the sulfation pattern
of CS present in serglycin is regulated during differentiation of
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monocytes to macrophages (44, 45). In macrophages serglycin
is substituted in a higher degree with CS-E compared to mono-
cytes which contain CS-4 chains. The amount of CS-E expressed
by macrophages can be further increased upon activation of dif-
ferentiated macrophages with phorbol 12-myristate 13-acetate
(PMA) (46).
STRUCTURE AND REGULATORY ELEMENTS OF THE HUMAN
SERGLYCIN GENE
The human serglycin gene is located in chromosome 10q.22.1 (47,
48) and is consisted by an approximately 1.8 kb of 5′-flanking
DNA, three exons, which are separated by two introns of 8.8 kb
(intron 1) and 6.7 kb (intron 2) (49, 50). The 5′-untranslated
mRNA and the hydrophobic 27 aminoacid signal peptide of the
translated protein are encoded in the first exon, whereas the sec-
ond exon encodes a 49 aminoacid peptide that represents the
amino-terminus of the mature serglycin core protein. Finally, the
larger exon 3 codes a 82 aminoacid peptide that contains the GAG
attachment region, the carboxy-terminus, and the 3′-untranslated
mRNA region (49) (Figure 1). An alternative spliced variant of
serglycin lacking exon 2 has been detected in neutrophils and in
low levels in HL-60 and may be related with the maturation of
promyelocytes to form segmented neutrophils (15). Several puta-
tive regulatory sites are present in the 5′-flanking region with E-26
specific family of transcription factors (ETS) site (−80) and the
cyclic AMP response element (CRE) half site at−70 to be the most
important regulatory elements for constitutive expression (51)
(Figure 1). The CRE site is also important for the induced expres-
sion of serglycin after treatment with PMA and dibutyryl cyclic
AMP (dbcAMP) (51). ETS regulatory elements interact with ETS1
and Friend leukemia integration 1 transcription factor proteins
(FLI1). The expression of serglycin was shown to be up-regulated
in a number of leukemic cell lines, ones that coincidentally have
been shown to express high levels of ETS1 and FLI1 (9, 52). The
ETS genes encode transcription factors that play important roles
in hematopoiesis, angiogenesis, and organogenesis. In the intron
1 a commonly conserved 70 bp Donehower element is found that
may has a cis-acting functional role (49). The serglycin gene has
also 21 Alu elements, with two of them being located in the 5′-
flanking region, 8 in the intron 1, and 11 in the intron 2 (49)
(Figure 1). Alu elements represent one of the most successful of
all mobile elements and are primate specific. Alu element inserts
in or near a gene have the potential to influence expression of that
gene in several ways (53). The expression of serglycin in different
cell lines depends also on the methylation status and the presence
of DNaseI hypersensitivity sites (DHSS) within the serglycin gene
(49, 54). Cell-specific DHSS sites have been found in the promoter
region, exon 2 and introns of serglycin gene in hematopoietic and
endothelial cells (51, 54). These sites are short chromatin regions
with disturbed nucleosome formation that have increased sensi-
tivity to factors interacting with DNA and regulate transcription.
Several of the DHSS appear to be located well within or very close
to Alu repeats and this association may play a role in the expression
of serglycin (54).
BINDING PARTNERS OF SERGLYCIN
Several studies have demonstrated that serglycin is capable to inter-
act with biological important molecules (summarized in Table 1).
The binding is mediated either through GAG chains or core pro-
tein or both moieties are required for high affinity binding to
serglycin. CS chains of serglycin mediate the binding to CD44
(55), whereas CS-4 chains with a high proportion of 4-sulfated
disaccharides (more than 87%) are required for binding to com-
plement components C1q and mannose binding lectin (MBL)
(56). Although CS-4 chains are crucial for binding of serglycin
to MBL (56) and collagen type I (57), the overall structure may
FIGURE 1 | Schematic representation of the structure of human serglycin (SRGN) gene and protein. (1) Putative regulatory sites in SRGN promoter.
Glucocorticoid response element (GRE), specificity protein-1 (SP-1). (2) Location of the Alu elements in the SRGN gene. (3) Encoded SRGN core protein. (bp,
base pairs; aa, aminoacid).
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Table 1 | Overview of serglycin binding partners.
Molecule Interaction type (Reference) Major functions
CELL-SURFACE RECEPTORS, CHEMOKINES, CYTOKINES, AND COMPLEMENT COMPONENTS
CD44 Physical association (55) Cell signaling, adhesion, migration and, lymphocyte activation,
hematopoiesis, tumor metastasis
CD53 Computational (experimental knowledge based) (86) Cell signaling, development, activation, growth, and motility. Activation of
leukocytes
HLA-DRA Computational (experimental knowledge based) (86) Antigen presentation, immune system response
CXCR4 Computational (experimental knowledge based) (86) Chemotaxis and activation of leukocytes, hematopoietic stem cell homing,
cancer cell metastasis
CXCL1 Colocalization (22) Chemotaxis, inflammation, angiogenesis, tumor growth
CXCL4 Physical association (60) Platelet aggregation, chemotaxis, hematopoiesis, angiogenesis, immune
system response
CCL3 Physical association (60) Chemotaxis, inflammation
BMP-like protein Physical association (60) Bone and cartilage formation
C1q Physical association (56) Complement activation
MBL Physical association (56) Complement activation
MATRIX MOLECULES/COMPOUNDS
Collagen I Physical association (57) Matrix organization, cell adhesion
Fibronectin Physical association (12, 58, 59) Matrix organization, cell adhesion, and migration
B2M Computational (experimental knowledge based) (86) Associates with MHC class I molecules. Implicated in amyloidosis and
multiple myeloma
Hydroxyapatite Physical association (16) Bone formation
PROTEOLYTIC ENZYME, PORE FORMING PROTEINS
Lysozyme Physical association (60) Anti-microbial activity
GZMB Physical association (61–63) Proteolysis, cell death
PRF1 Physical association (61–63) Pore formation, cell death
Chymases Physical association (64, 65) Proteolysis as part of host defense and inflammation
Tryptases Physical association (65–67) Proteolysis as part of host defense and inflammation
CPA Colocalization (68) Proteolysis as part of host defense and inflammation
Elastase Colocalization (71) Proteolysis as part of host defense and inflammation
tPA Colocalization (23) Fibrinolysis. Proteolysis in physiological conditions and diseases
MMP13 Physical association (19) Proteolysis in physiological conditions and diseases
proMMP9 Physical association (73, 74) Proteolysis in physiological conditions and diseases
NEUROTRANSMITTERS
Serotonin Colocalization (69) Neurotransmission, vasoconstriction, thrombosis
Histamine Colocalization (69) Neurotransmission, endothelium permeabilization, inflammation
Dopamine Colocalization (70) Neurotransmission
INTRACELLULAR PROTEINS
CEP70 Physical association (75–77) Microtubules organization
BAG6 Physical association (75–77) Quality control of proteins, proteasome assembly and degradation, T cell
response
PSRC1 Physical association (75–77) Mitotic spindle assembly
UBR4 Physical association (75–77) Ubiquitination, proteasomal, and lysosomal degradation
UBQLN4 Physical association (75–77) Binds ubiquitinated proteins, proteasomal degradation
SGTA Physical association (75–77) Cochaperone, quality control of proteins
ARHGDIB Computational (experimental knowledge based) (86) Cell signaling, proliferation, cytoskeletal organization, and secretion. Cancer
invasion and metastasis
LAPTM5 Computational (experimental knowledge based) (86) Lysosomal destabilization, cell death
ALOX5AP Computational (experimental knowledge based) (86) Leukotriene synthesis, inflammation
MSN Computational (experimental knowledge based) (86) Links plasma membranes with actin cytoskeleton. Cell signaling and
movement
HCLS1 Computational (experimental knowledge based) (86) Cytoskeleton remodeling, leukocyte chemotaxis, and activation
RAP1B Computational (experimental knowledge based) (86) Cell signaling, adhesion, growth, and differentiation
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also be important for high affinity binding. This is in agreement
with previous studies where the CS-4 chains were essential for
binding of serglycin to molecules, such as fibronectin and colla-
gen, chemokine (CXC motif) ligand 4 (CXCL4), chemokine (C-C
motif) ligand 3 (CCL3), bone morphogenetic protein (BMP)-like
protein, lysozyme, granzyme B (GZMB), perforin (PRF1), and
hydroxyapatite although the intact serglycin molecule might inter-
act more efficiently with these molecules (12, 16, 58–63) (Table 1).
HP or/and CS-E chains of serglycin in mast cells mediate its bind-
ing to chymases (64, 65) and tryptases (65–67) (Table 1). Serglycin
colocalizes with carboxypeptidase A (CPA) (68), serotonin, his-
tamine (69), and dopamine (70) in mast cell granules, CPA in
pancreatic acinar cells (18), neutrophil elastase in neutrophils (71)
and U937 promonocytes (72), tissue-type plasminogen activator
(tPA) (23) and chemokine growth-related oncogene-alpha (GRO-
α/CXCL1) in endothelial cells (22). Serglycin is capable to interact
with matrix metalloproteinases (MMPs), such as MMP13 (19)
and proMMP9 through its core protein (73, 74) (Table 1). By
using stringent high-throughput yeast two-hybrid system interac-
tions, novel serglycin ligands, such as centrosomal protein 70 kDa
(CEP70), BCL2-associated athanogene 6 (BAG6), proline/serine-
rich coiled-coil 1 (PSRC1), ubiquitin-protein ligase E3 compo-
nent n-recognin 4 (UBR4), ubiquilin 4 (UBQLN4), and small
glutamine-rich tetratricopeptide repeat (TPR)-containing alpha
(SGTA) have been identified (75–77) (Table 1). Among them
CEP70 and PSRC1 participate in microtubules formation and
assembly of mitotic spindle (78, 79), whereas SGTA and BAG6
play key roles in quality control processes for newly synthesized
proteins via their ubiquitination and proteasome degradation
(80). Recently, it was shown that BAG6 is not only involved in
proteasome core particle assembly but also has a key role in
efficient regulatory particle assembly by directly associating with
precursor regulatory particles (81). UBR4 and UBQLN4 are also
involved in the proteasomal degradation of proteins. UBR4 is an
E3 ubiquitin-protein ligase that mediates polyubiquitination of
low-abundance regulators and selective proteolysis through the
proteasome but is also associated with cellular cargoes destined
to autophagic vacuoles and degradation through the lysosome
(82, 83). UBQLN4 binds either to ubiquitinated or not proteins
and promotes their proteasomal degradation (84) but also medi-
ates the recruitment of ubiquilin1 to autophagosomes (85). In
another study, Wu et al. (86) constructed a protein functional
interaction network that suggests association of serglycin with
known and novel proteins, such as Rho GDP dissociation inhibitor
(GDI) beta (ARHGDIB), CCL3, lysosomal protein transmem-
brane 5 (LAPTM5), arachidonate 5-lipoxygenase-activating pro-
tein (ALOX5AP), chemokine (C-X-C motif) receptor 4 (CXCR4),
beta-2 microglobulin (B2M), moesin (MSN), hematopoietic cell-
specific Lyn substrate 1 (HCLS1), GZMB, RAP1B, member of RAS
oncogene family, major histocompatibility complex, class II, DR
alpha (HLA-DRA) (see Table 1). A summary of serglycin inter-
actions is available in http://www.ebi.ac.uk/Tools/webservices/
psicquic/view/main.xhtml?query=srgn. A large number of can-
didate molecules might associate with serglycin according to
STRING database. A diagram with predicted functional part-
ners for serglycin (confidence score >0.48) is given in Figure 2
(http://string-db.org/).
PHYSIOLOGICAL ROLES OF SERGLYCIN IN INFLAMMATION
Serglycin synthesized by inflammatory and stromal cells is secreted
either constitutively or in a regulated manner. Serglycin secretion
can be induced in several cell types upon external inflamma-
tory stimulation. The biosynthesis of serglycin is up-regulated by
liposaccharide (LPS) in macrophages (87), tumor necrosis factor
(TNF) in endothelial cells (23) and adipocytes (88) and interleukin
1β (IL-1β) in smooth muscle cells (21).
The generation of serglycin−/− mice has demonstrated a wide
impact of serglycin on the functional properties of immune cells.
In inflammatory cells serglycin is localized in secretory granules
and vesicles participating in crucial roles in intracellular storage
and secretion of bioactive molecules (Figure 3). In mast cells, ser-
glycin is implicated in the storage of granule-localized proteases
such as chymases, tryptases and CPA (34,68),histamine, serotonin,
and dopamine in mast cells (69, 70). Serglycin forms complexes
with mast cell proteases modulating their activities. Several studies
have addressed functions linked to HP, the major GAG compo-
nent of serglycin, in mast cells. HP/chymase complexes bind to
HP-binding substrates of the enzyme thus presenting them to
chymase and enhancing their proteolysis (89). HP on serglycin
was shown to significantly block the inhibition of chymase by
natural inhibitors such as alpha 1-protease inhibitor, alpha 1-
antichymotrypsin, alpha 2-macroglobulin, and soybean trypsin
inhibitor (90, 91). HP is also involved in the formation of active
tryptase tetramers (92, 93). It is suggested that serglycin apart from
its protective role for partner molecules is also linked to trans-
port to target sites, where proteases are released to perform their
functions (94).
Serglycin mediates the storage of GZMB but not of granzyme
A in cytotoxic T lymphocytes (CTLs) (95). It is also essential for
the storage of elastase in azurophil granules of neutrophils. In
contrast, serglycin is not involved in the storage of other gran-
ule components such as cathepsin G and proteinase 3 in these
cells (71). Similarly, knockdown of serglycin in platelets results in
defective storage of CXCL4, CXCL7, and platelet-derived growth
factor (PDGF) (96). The impaired storage of mast cell proteases,
neutrophil elastase, GZMB in CTLs and CXCL4 in platelets was
not due to altered mRNA levels coding for these molecules, sug-
gesting a crucial role for serglycin on storage rather than mRNA
expression. The ability of serglycin to promote storage of granule
components is suggested to be due to specific electrostatic interac-
tions between the sulfated GAG chains and the basically charged
regions of secretory granule components (95). The stable expres-
sion of granule components followed by their diminished protein
levels in serglycin knockdown cells and the association of serglycin
with SGTA, BAG6, UBR4, and UBQLN4, which are involved in
quality control during biosynthesis and degradation of proteins,
might suggest a regulatory role for serglycin in cytoplasmic quality
control machinery.
Serglycin is also involved in apoptosis and immune regula-
tion. Diminished storage of mast cell proteases in serglycin−/−
mice resulted in reduced sensitivity of mast cells to apoptosis as
a consequence of the reduced granule damage, reduced release
of proteases into the cytosol, and defective caspase-3 activation
(97). Mast cells lacking serglycin expression preferentially died
by necrosis rather than apoptosis and the necrotic phenotype of
Frontiers in Oncology | Molecular and Cellular Oncology January 2014 | Volume 3 | Article 327 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Korpetinou et al. Serglycin in inflammation and malignancy
FIGURE 2 | Overlay of predicted functional partners for human
serglycin (SRGN). Molecules have been classified according to their
confidence score (higher to lower, confidence score >0.48): GZMB, serpin
peptidase inhibitor (SERPING1), albumin (ALB), platelet factor 4/CXCL4
(PF4), CD44, fibronectin 1 (FN1), tissue matrix metalloproteinase inhibitor 1
(TIMP1), multimerin 1 (MMRN1), plasminogen (PLG), clusterin (CLU),
coagulation factor XIII, A1 polypeptide (F13A1), TGFB1, serpin peptidase
inhibitor, clade A member 1 (SERPINA1), epidermal growth factor (EGF),
aldolase A (ALDOA), coagulation factor VIII (F8), growth arrest-specific 6
(GAS6), alpha-2-macroglobulin (A2M), amyloid beta (A4), precursor protein
(APP), CXCL7 (PPBP), coagulation factor V (F5), actinin, alpha 1 (ACTN1),
TGFB2, actinin, alpha 2 (ACTN2), complement factor D (CFD), serpin
peptidase inhibitor, clade F (SERPINF2), c-fos induced growth
factor/vascular endothelial growth factor D (FIGF), vascular endothelial
growth factor C (VEGFC), kininogen 1 (KNG1), actinin, alpha 4 (ACTN4),
TGFB3, secreted protein, acidic, cysteine-rich/osteonectin (SPARC), serpin
peptidase inhibitor, clade E (SERPINE1), serpin peptidase inhibitor, clade H
(SERPINH1), PRF1, LAPTM5, TYRO protein tyrosine kinase binding protein
(TYROBP), CD53, CCL3, glia maturation factor, gamma (GMFG), pleckstrin
(PLEK), THEMIS2/thymocyte-expressed molecule involved in selection
protein 2 (C1orf38), cathepsin S (CTSS), CD48, HCLS1; UBQLN4; protein
tyrosine phosphatase, receptor type, C (PTPRC), integrin, beta-2 (ITGB2),
ecotropic viral integration site 2B (EVI2B), neutrophil cytosolic factor 2
(NCF2) (http://string-db.org/).
serglycin−/− mast cells was linked to defective degradation of
poly(ADP-ribose) polymerase-1 (98). Serglycin binds to GZMB
and acts as a vehicle for its delivery from CTLs into target cells
(62, 63). The impaired storage of GZMB in CTLs and NK cells
in serglycin−/− mice may affect their potential to promote killing
of neighbor cells (95, 99). Interestingly, serglycin−/−mice infected
with lymphocytic choriomeningitis virus are capable to clear virus
as efficient as wild type animal but the contraction of the CD8+
cells is delayed in serglycin−/− mice, and this could be attributed
to sustained proliferation of the CD8+ cells. The impaired storage
of elastase in neutrophils is possibly associated with the reduced
capacity of serglycin−/−mice to clear Klebsiella pneumoniae infec-
tion (71), whereas after Toxoplasma gondii infection only delayed
recruitment of neutrophils and lower levels of IL-6 secretion were
demonstrated at early stages of the infection without significant
immune response impairment (100).
Another interesting implication of serglycin in the regulation of
immune system is its ability to inhibit complement system activity.
Serglycin isolated from multiple myeloma (MM) cells inhibits the
classical and the lectin pathways of complement system through
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FIGURE 3 | Potential roles of serglycin (SRGN) in inflammation and
malignancy. (1) Tumor cells and platelets secrete SRGN, which is
subsequently bound on their surface via CD44 and/or other receptors, such as
P-selectin. Direct and/or indirect (via SRGN) platelet-tumor cell contacts induce
EMT, enhance invasiveness, and promote metastasis by binding to P-selectin
and/or other receptors present on endothelial cells. (2) SRGN synthesized by
inflammatory/stromal and tumor cells is either constitutively secreted or
transported to storage granules for subsequent regulated secretion.
SRGN-bound molecular effectors (cytokines, chemokines, complement
components, growth factors, proteases, MMPs, histamines, and others) are
then specifically delivered to target cells, thus controlling inflammation and
tumor progression. (3) SRGN present on tumor cell surface promotes their
adhesion to collagen I inducing the expression of MMP2/MMP9 resulting in
bone destruction and peritumorous ECM breakdown.
binding to C1q and MBL. CS-4 chains with a high proportion
of 4-sulfated disaccharides are required for the interactions with
complement proteins (56). CS-E and in a lower extent HP com-
pete with CS-4 chains of serglycin for binding to C1q, whereas only
CS-E competes for binding to MBL. Serglycin secreted by various
immune cells that carries CS-E or/and HP is more likely capable
to regulate the activity of both pathways (56).
In a recent study serglycin was found to be among the most
abundantly expressed genes in epicardial adipose tissue and was
up-regulated with pro-inflammatory genes such as IL-1β, IL-6,
IL-8, and chemokine receptor 2 (CCR2) (88). In human umbil-
ical vein endothelial cells (HUVECs) the storage of CXCL1 in
secretory vesicles to the apical side was partly depended on ser-
glycin, whereas upon stimulation with IL-1β an increased colo-
calization of the two molecules inside the vesicles before secre-
tion was observed suggesting a possible involvement of serglycin
in inflammatory conditions (22). The presence of serglycin in
platelets may be also important for these cells to fully display their
pro-inflammatory properties. In platelets, serglycin associates with
fibronectin, PDGF, CXCL7, CXCL4, RANTES/CCL5, and CCL3
and its absence leads to reduced storage of PDGF, CXCL4, and
CXCL7 in α-granules, contributing to defective platelet aggrega-
tion and leukocyte activation (96). Serglycin expression is elevated
in the dermal vessels in dermatomyositis, a chronic inflamma-
tory disease of the skin (101). In addition, mRNA expression of
serglycin is induced upon UVB radiation and IL-1α exposure in
cultured human dermal fibroblasts suggesting that serglycin may
participate in dermal inflammation (25).
EXPRESSION AND BIOLOGICAL ROLES OF SERGLYCIN IN
MALIGNANCIES
Although the main function of serglycin in the biology of immune
cells is the proper formation of secretory granules and vesicles as
well as the storage and secretion of several components in the
extracellular matrix (ECM), the role of serglycin in malignan-
cies is rather intriguing. Serglycin seems to participate in tumor
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development in a manner that at least partially requires inter-
actions between tumor cells and their microenvironment (102)
(Figure 3).
Serglycin with different GAG chains and sulfation patterns
is expressed in numerous human hematopoietic and non-
hematopoietic tumors (8–17, 26, 27, 30, 55, 103). Interestingly,
the megakaryocytic tumor cells synthesize a hybrid CS/HS ser-
glycin (12). The expression levels of serglycin may vary during
hematopoietic cell differentiation (9, 14, 15) and is constitu-
tively secreted in the ECM in hematopoietic and solid tumors
(16, 30). Serglycin has been proposed as a selective biomarker for
acute myeloid leukemia compared to Philadelphia chromosome-
negative chronic myeloproliferative disorders since it is highly
expressed only by leukemic blasts of patients with acute myeloid
leukemia and not in acute lymphocytic leukemia (10). Expression
of serglycin has been demonstrated in a variety of lymphoma,
myeloma, mastocytoma, and thymoma cells. In these cells the
presence of CS-4 or CS-6 side chains of serglycin are required
for binding to CD44, whereas serglycin carrying HS or HP is not
capable for binding to CD44 (17, 55). Secreted serglycin in the
tumor microenvironment may interact with CD44 on tumor cells
triggering CD44 signaling (Figure 3). CD44 is involved in cell–cell
and cell-matrix interactions and signals through several pathways
by binding via its cytoplasmic domain to multiple cell membrane
and intracellular functional proteins thus regulating cancer cells’
epithelial to mesenchymal transition (EMT), migration, metasta-
sis, proliferation, apoptosis, and resistance (104, 105). Importantly,
CD44 has been recognized as a cancer stem cell marker for a variety
of tumor types.
The expression of serglycin was also confirmed in several MM
cell lines (16). Serglycin is the major PG synthesized by MM cells
and is constitutively secreted to the culture medium. Interestingly,
serglycin is also localized on the cell surface where it is attached
through its CS-4 chains. Serglycin levels are elevated in the bone
marrow aspirates of patients with newly diagnosed MM, suggest-
ing a potent correlation of serglycin accumulation with disease
progression (16). Serglycin present on myeloma cell surface pro-
motes the adhesion of myeloma cells to collagen I. The adhesion
of myeloma cells to collagen I but also the interaction of soluble
collagen I with myeloma cells via cell-surface serglycin enhances
the biosynthesis and secretion of MMP2 and MMP9, which are
involved in bone destruction (57) (Figure 3). The regulatory role
of serglycin in the biosynthesis and secretion of proteases has been
also shown in other cellular systems (23, 106). Serglycin is colo-
calized with tPA in secretory vesicles in HUVEC (23), whereas
Madin-Darby canine kidney cells stably transfected with serglycin
express elevated levels of MMP9 and urokinase plasminogen acti-
vator (uPA) both at mRNA and protein levels (106). The release
of proteolytic enzymes by tumor cells or stromal cells and the
regulation of their activity in the tumor microenvironment are
crucial for tumor progression and tumor-induced bone disease
(107, 108). In addition, secreted serglycin was found to influence
the bone mineralization process through inhibition of the crys-
tal growth rate of hydroxyapatite, thus providing another possible
explanation for impaired bone formation and loss of bone mass
commonly seen in MM patients (16). Serglycin synthesized and
secreted by human acute monocytic leukemia cell line THP1 as
well as serglycin isolated from myeloma cells forms complexes with
proform of MMP9 (proMMP9) in vivo and in vitro (73, 74). Both
the hemopexin-like (PEX) domain and the fibronectin-like (FnII)
module of the enzyme are involved in the formation of the het-
eromer. The formation of heteromers alters the mode of activation
of proMMP9 and the interaction of the enzyme with its substrates
(73, 109). Another study supports the direct protein–protein inter-
action between serglycin and MMPs (19). It has been shown
that serglycin is colocalized with MMP13 in cytoplasmic gran-
ules in chondrocytes interacting with a fragment of C-terminal
domain of MMP13 that comprises the hinge and PEX domains
(19). ProMMP9 in the heteromer is activated in the presence of
Ca2+, although this cation stabilizes MMP9 without activating
the single proenzyme. Ca2+ induces the cleavage of both the C-
terminal PEX domain of the enzyme and the core protein of PG
and the release of the activated enzyme. MM located within bone
marrow and solid tumors, which metastasize in the bones, induce
bone destruction and release Ca2+. The accumulation of serglycin
within bone marrow in MM may be involved in the formation of
heteromers with proMMP9 in the ECM triggering a Ca2+-induced
activation of the enzyme (Figure 3).
Matrix secreted and cell-surface associated serglycin pro-
tects myeloma cells from complement system attack induced by
immunotherapy, therefore promoting the survival of myeloma
cells (56). Serglycin inhibits specifically the classical and the lectin
pathways via binding to C1q and MBL and do not interfere with the
alternative pathway (56) (Figure 3). The intact serglycin molecule
is required for binding to MBL, whereas binding to C1q is medi-
ated exclusively by CS-4 side chains. A similar mode of inhibition
of the classical and lectin pathways was demonstrated for secreted
serglycin by aggressive breast cancer cells (110). It has been shown
previously that complement components such as C1q, C3, C3a,
C4, C5, and the membrane attack complex (MAC) are deposited in
the inflammatory tumor microenvironment. The assumption has
been made is that these activated complement proteins play a role
in tumor defense directly through complement-dependent cyto-
toxicity and indirectly through antibody-dependent cell-mediated
cytotoxicity (111). The mechanism of complement activation in
cancer is known to involve mainly the classical and the lectin path-
ways (111). Complement is activated by factors present on tumor
cells or induced by treatment of tumor cells with therapeutic anti-
bodies. Malignant cells express a variety of complement inhibitors,
which all attenuate complement cytotoxicity (111). The inhibition
of complement is also a great limitation during immunotherapy
against several types of cancer. These data suggest a role for ser-
glycin as a modulator of immune system response in the tumor
microenvironment that may protect tumor cells from complement
attack. Another great limitation in the treatment of malignancies
is the development of drug resistance. Serglycin is among genes
that over-expressed in six tumor cell lines of hematopoietic origin
that resist in doxorubicin, methotrexate, cisplatin, and vincristine
treatment compared to the drug sensitive parental cell lines (112).
The implication of serglycin in drug resistance is of great interest
and the mechanism of action is yet unknown.
Only few studies have demonstrated expression of serglycin
in non-hematological tumors. Increased expression of serglycin
in patients with hepatocellular and nasopharyngeal carcinoma
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was correlated with unfavorable prognosis and represented an
independent unfavorable prognostic indicator for overall sur-
vival and recurrence as well as disease free and distant metastasis
free survival (30, 103). Metastatic nasopharyngeal carcinoma cells
highly express and secrete in the culture medium serglycin, which
promotes motility, invasion, and metastasis (30). The overexpres-
sion of serglycin is also associated with EMT in nasopharyngeal
cancer cells. The functions of serglycin were dependent on the fully
glycosylated molecule. Treatment of cancer cells with exogenously
added glycanated serglycin promoted cancer cell metastasis and
invasion, whereas non-glycosylated core protein of serglycin failed
to induce cell motility (30). In vitro, serglycin was highly expressed
and secreted by aggressive tumor cell lines (110). In invasive MDA-
MB-231 breast cancer cells serglycin represents the major PG type
and is abundantly expressed and secreted in the culture medium
(110). Furthermore, serglycin is highly expressed by other aggres-
sive breast cancer cells, which also belong to the Basal B subgroup,
and they show mesenchymal phenotype, enhanced invasive prop-
erties and enriched expression of EMT transcriptional drivers
(113). These cells exhibit an EMT gene signature and are found to
resemble breast cancer stem cells, being CD44highCD24low (114).
Interestingly, stable overexpression of intact serglycin gene and
a truncated form of serglycin lacking GAG attachment sites in
low aggressive MCF-7 breast cancer cells demonstrated that ser-
glycin promotes breast cancer cell anchorage-independent growth,
migration, and invasion. The tumor promoting properties of
serglycin are dependent on the overexpression and secretion of
glycanated serglycin (110). Therefore, the specific structure of CS-
4 present on serglycin is important for serglycin functions in breast
cancer. Altered biosynthesis of CS chains has been demonstrated
in various cancer types. Specific structures of CS influence vari-
ous biological processes during tumor growth and spread (115).
CHST11 gene that specifically mediates 4-O sulfation of CS is
highly expressed in MDA-MB-231 breast cancer cells and breast
cancer tissues. CS-4 chains mediate the binding of breast cancer
cells to P-selectin and facilitate the formation of metastasis (116).
INFLAMMATION AUGMENTS MALIGNANCY: POSSIBLE
ROLES OF SERGLYCIN
During tumor development, cancer cells produce cytokines and
chemokines that attract and activate inflammatory cells, endothe-
lial cells, fibroblasts, and platelets to secrete growth factors,
cytokines, and chemokines. Serglycin may regulate the biosynthe-
sis, secretion, and targeted delivery of many inflammatory media-
tors, which can act in various cell types in paracrine and autocrine
manner in multiple ways to enhance inflammatory process and
support tumor growth and metastasis (Figure 3).
Tumors are often infiltrated by immune cells, such as T lym-
phocytes, mast cells, and macrophages, which are recruited to the
site by chemokines and cytokines secreted by the various cells in
the tumor milieu. Macrophages are attracted by responding to
CCL2, IL-4, IL-10, and IL-13, acquire an activated phenotype with
pro-tumorigenic properties, releasing a variety of chemokines,
cytokines, growth factors, and proteases (117). Mast cells infil-
tration is occurred in the tumor microenvironment in a number
of human malignancies in response to tumor-derived chemoat-
tractants such as CCL2 and CCL5. The presence of mast cells was
shown to correlate with either favorable or poor prognosis depend-
ing on the tumor. Mast cells can exert pro-tumorigenic effects by
secreting factors like VEGF, angiopoietin-1, CXCL1, and IL-8 that
promote tumor angiogenesis, as well as growth factors such as
PDGF, NGF, SCF, FGF2, and proteases that facilitate tumor cell
growth and metastases (118). Mast cell proteases exert dual roles in
the regulation of inflammatory process. Several pro-inflammatory
chemokines and cytokines are substrates of mast cell proteases and
their cleavage results in the activation or inactivation of inflam-
matory mediators (119). Chymase also indirectly influences ECM
remodeling via its ability to activate various MMPs (120, 121).
Both tryptase and chymase are directly involved in ECM degra-
dation. Tryptase degrades collagen type IV present in basement
membranes while chymase cleaves vitronectin and procollagen
and both degrade fibronectin (119).
Endothelial cells synthesize and secrete chemokines, cytokines,
and growth factors such as CXCL1 and respond to inflamma-
tory stimuli enhancing their production in a serglycin-depended
manner (22). Cancer associated fibroblasts which are activated
by cancer cells also overexpress inflammatory mediators as
well as serglycin and a disintegrin and metalloproteinase with
thrombospondin motifs 1 (ADAMTS1), promoting cancer cell
invasion (24).
Considering that single GAG chains and serglycin interact with
growth factors, cytokines, and chemokines (7, 122), it is plausible
that serglycin secreted by cancer and stromal cells is important
for the protection of inflammatory mediators in ECM and the
creation of chemotactic gradients. Furthermore, serglycin may be
involved in the presentation of these molecules to high affinity
receptors thus enhancing signaling events (Figure 3).
Platelets have long been believed to play a critical role in can-
cer metastasis through the enhancement of circulating tumor
cells survival and adhesion to the endothelium in the circula-
tion (123). Serglycin may be involved in tumor cell metastasis
either via its proven role in activation of platelets or directly
affecting the binding of tumor cells to platelets (Figure 3). The
presence of serglycin in platelets is critical for packaging and
secretion of selected α-granule proteins. The reduced secretion of
dense granule contents results in impaired platelet activation and
aggregation (7, 96). Tumor cells may bind to the surface of acti-
vated platelets via platelet receptors glycoprotein IIb/IIIa (integrin
αIIbβ3) and P-selectin or by attachment to platelets micropar-
ticles. This most likely requires the activation of platelets, the
fusion of α-granule membrane with the cell membrane, the expo-
sure of activation-induced surface proteins and the secretion of
chemokines, cytokines, and growth factors (7). Platelet serglycin
may influence the release of these factors in the tumor microen-
vironment, which promote tumor cell growth and metastasis.
Platelet-derived TGF-β as well as direct platelet-tumor cell con-
tacts synergistically activate the TGF-β/Smad and nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) path-
ways in cancer cells, resulting in their transition to an invasive
mesenchymal-like phenotype and enhanced metastasis in vivo
(124) (Figure 3). Another possibility is that released serglycin
either by tumor cells or platelets may participate in bridging tumor
cells with activated platelets or platelet microparticles as well as
endothelial cells. It is proposed that serglycin is bound on the
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surface of platelets (7), whereas serglycin has been identified on
the surface of tumor cells (6, 16). Secreted serglycin substituted
with CS chains may associate with tumor cell surface via CD44
(55) and the membrane of activated platelets and endothelial cells
via P-selectin (116) and/or other unidentified receptors (Figure 3).
The inhibition of platelets-tumor cell interaction has been targeted
for treatment of metastasis. HP and other GAGs isolated from
various sources prevent metastasis. Although the anti-metastatic
effect of HP was initially believed to associate with its anticoag-
ulant activity, later it was found that interfered with binding of
activated platelets with ligands on tumor cells (125).
CONCLUSION
Serglycin is a dominant PG in immune cells with a major impact
on their biology. Numerous studies in the past using mainly a
valuable serglycin knockdown mouse model demonstrated impor-
tant functional roles for serglycin in immune system processes
and inflammation. Recent studies have revealed emerging roles
for serglycin in tumorigenesis. Collectively, the expression of ser-
glycin seems to benefit tumor cells in multiple ways. It may act as
a modulator of immune system in tumor microenvironment and
enrich tumor cells with resistance to various therapeutic agents.
Serglycin augments the invasion and metastasis of tumor cells with
yet unknown molecular mechanisms. Importantly, it serves as an
ideal molecular partner for multiple molecular effectors, such as
proteolytic enzymes, chemokines, cytokines, and growth factors
regulating their biosynthesis and secretion or/and enhancing their
activities by protecting and accompanying them to specific target
sites.
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